Replies to post #126720 on Biotech Values

[poorgradstudent]

Hopefully this turns out to be an issue of the drug, not the target, and an SGEN PSMA-targeting ADC turns out to be > than an IMGN PSMA-targeting ADC.

You may be right. At the MLNM gave no indication that they were working to improve the linker that they got form IMGN they way Genentech has. However, there was talk that one of the big factors for the failure of the PSMA drug was that the target is shed copiously into the circulation. As you can imagine, this can produce a kind of "sink" for the toxin-PSMA Ab construct, reducing the amount that gets to the tissue.